Sign In
Buy ALT
$2.92
+0.0500 (+1.74%)
At Close: Jun 04, 2026
ALT5 Sigma Reports Fiscal Financial Results for Second Quarter 2024
06:30pm, Monday, 19'th Aug 2024
Q2 Fintech results only include the period commencing May 15, 2024, the date on which the ALT 5 Sigma acquisition closed, to June 30, 2024 LAS VEGAS, NV / ACCESSWIRE / August 19, 2024 / ALT5 Sigma Cor
3 Promising Biotech Stocks for the Long-Term: August 2024
02:00pm, Tuesday, 13'th Aug 2024
Some of the best biotech opportunities can be found in oversold obesity treatment stocks. Look at Eli Lilly (NYSE: LLY ), for example.
ALT5 Sigma Reports 114% Year-Over-Year Increase in Transaction Volume for the Month of July 2024
08:30am, Tuesday, 13'th Aug 2024
LAS VEGAS, NV / ACCESSWIRE / August 13, 2024 / ALT5 Sigma Corporation (NASDAQ:ALTS), a fintech, providing next generation blockchain-powered technologies for tokenization, trading, clearing, settlemen
The 7 Best Under $10 Stocks to Buy in August 2024
09:00am, Sunday, 11'th Aug 2024
To understand the allure of buying the best stocks under $10, it's a good idea to go back to basics. A stock's price reflects how much you pay for one dollar of a company's earnings.
Altimmune, Inc. (ALT) Q2 2024 Earnings Call Transcript
09:03am, Saturday, 10'th Aug 2024
Altimmune, Inc. (NASDAQ:ALT ) Q2 2024 Earnings Conference Call August 8, 2024 8:30 AM ET Company Participants Lee Roth - Burns McClellan, Investor Relations Advisors-Altimmune Vipin Garg - Chief Execu
Prediction: This Weight Loss Stock Will Be Acquired Within the Next Year
08:46am, Friday, 09'th Aug 2024
Weight loss treatments such as Ozempic, Wegovy, Mounjaro, and Zepbound are big players in the diabetes and obesity care markets. One risk of losing weight is shedding too much muscle mass.
Altimmune Announces Second Quarter 2024 Financial Results and Provides a Business Update
07:00am, Thursday, 08'th Aug 2024
Recent presentations at major medical meetings provide further support for the differentiated profile of pemvidutide in obesity and metabolic dysfunction-associated steatohepatitis (MASH)
The weight loss space is dominated by Eli Lilly and Novo Nordisk, which produce the leading medications. Viking Therapeutics, Altimmune, Pfizer, and Roche are all looking to enter the red-hot weight l
Altimmune to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
07:30am, Thursday, 01'st Aug 2024
GAITHERSBURG, Md., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2024 financial re
NEW YORK, July 30, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Altimmune, Inc. (NASDAQ: ALT) on
ALT5 Sigma Reports 99% Year-Over-Year Increase in Transaction Volume to Over US $879 Million for First Two Quarters of 2024
08:30am, Thursday, 25'th Jul 2024
LAS VEGAS, NV / ACCESSWIRE / July 25, 2024 / ALT5 Sigma Corporation (NASDAQ:ALTS), a fintech, providing next generation blockchain-powered technologies for tokenization, trading, clearing, settlement,
Weekly subcutaneous doses of pemvidutide resulted in up to 68.5% relative reduction in liver fat content (LFC), with up to 55.6% of subjects achieving LFC normalization after 12 weeks of treatment
Can These 2 Biotechs Beat Eli Lilly and Novo Nordisk in Weight-Loss Drugs?
09:30am, Saturday, 20'th Jul 2024
Eli Lilly and Novo Nordisk will need to share the weight-loss drugs market someday. Altimmune's candidate looks like it could succeed where their medicines struggle.
3 Undervalued Biotech Stocks With Breakout Potential
06:00am, Friday, 19'th Jul 2024
Undervalued biotech stocks will always be relevant for the savvy investor. The biotech world is evolving rapidly, with pharmaceutical giants tirelessly building on their pipelines and technologies.
Forget Boring Diversification! 3 Wild-Card Stocks to Spice Up Your Portfolio
02:25pm, Wednesday, 17'th Jul 2024
Tired of watching your portfolio crawl along? Standard investment advice often includes diversifying into bland, safe bets.
